Xeris Biopharma Holdings Inc
XERS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.88B
Close$
$2.89
74% downside
Current Fair Value
74% downsideOvervalued by 74% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.88 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.84 |
| Outstanding Shares | 172,823,455 |
Return
| Return on Equity | 176.34% |
|---|---|
| Return on Assets | -4.17% |
| Return on Invested Capital | 0.71% |
Valuation & Multiples
| P/E Ratio | -106.18 |
|---|---|
| PEG | -7.02 |
| Price to Sales | 11.13 |
| Price to Book Ratio | -11.13 |
| Enterprise Value to Revenue | 6.1 |
| Enterprise Value to EBIT | 1300.77 |
| Enterprise Value to Net Income | -120 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -29.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$90.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$101.68 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 64.35% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.93%▼ 62.57% |
|---|---|
| Total Invested | $15.57M▼ 98.21% |
| Investors Holding | 16▼ 235.00% |
ESG Score
No data
About Xeris Pharmaceuticals Inc
435 employees
CEO: paul Edick Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and ...